The objective: to evaluate the impact of Prosteks on Domain NIH CPSI (pain discomfort) and IIEF in patients with prostate pain syn drome (PBS).
Patients and methods. The sample consisted of 30 patients with an average age of PBS 37 years (min – 25, max – 51) in which the average duration of complaints was 10 months, ranging from 6 to 23. The criteria include: persistent or recurrent episodic pain con nects patients with prostate cancer, aggravated by its palpation; pain in the prostate can not be explained by any infectious agents or local pathological process. Exclusion criteria acute and chronic infectious and inflammatory diseases of the urogenital tract. Surveys during screening, microscopic examination of urethral material midstream urine and prostatic secretions to identify the inflammatory response. To identify C.trachomatis, M.genitalium, U.urealiticum, N.gonorrhoeae, T. vaginalis, G.vaginalis urethral material was investigated by PCR. To eliminate urinary tract infections culture research conducted midstream morning urine. Also before the start of therapy and after its termination patient survey was conducted using questionnaires NIH CPSI and IIEF Daily treatment: 1 suppository of Prosteks into the anus at night for 60 days.
Results. The 2 month course of therapy with Prosteks not affect the location of pain, but was significantly and clinically signifi cantly reduced the probability of their occurrence and intensity of the perineum, vagina and over during / after ejaculation. Options painful phenomena in areas such as the head of the penis, testicles and urination influenced Prosteksa not significantly changed. In addition, after treatment Prosteksom we reported clinically mean ingful and statistically significant changes in all domains of the scale IIEF. In particular, the median value of domains that charac terize an erection, orgasm / ejaculation, libido, satisfaction with sexual intercourse and sexual life as a whole increased by 6, 2, 2, 3 and 3 points
Conclusion. 2 month course of the drug Prosteks (1 suppository into the anus at night) was significantly and clinically significantly reduces the likelihood and intensity of pain in the perineum, vagina and over during / after ejaculation. Using PBS patients with rectal suppositories Prosteks within 2 months of clinically meaningful and statistically significant increases IIEF total score scale, characterizing erectile function, ejaculation / orgasm, satisfaction with sexual intercourse and sexu al life in general.
Given the clinical effects Prosteksa, it can be recommended for the management of patients with PBS, combined with sexual disorders
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
Stephens Shields AJ, Clemens JQ, Jemielita T, Farrar J, Sutcliffe S, Hou X, Landis JR. Symptom variability and early symptom regression in the MAPP study: a prospective study of urological chronic pelvic pain syndrome //J Urol. 2016 Nov;196(5):1450–1455.
Breser M.L., Motrich R.D., Sanchez L.R., Rivero V.E. Chronic pelvic pain development and prostate inflammation in strains of mice with different susceptibility to experimental autoimmune prostatitis //Prostate. 2017 Jan;77(1):94–104.
Wong L., Done J.D., Schaeffer A.J., Thumbikat P. Experimental autoimmune prostatitis induces microglial activation in the spinal cord. //Prostate. 2015 Jan;75(1):50–9.
Savateeva Liubimova TN, Sivak KV, Malinin VV. Effect of prostatilen AC suppositories on course of experimental prostatitis // Urologiia. 2012 Jul Aug;(4):50–54.
Gorpynchenko II, Iakovlev GM, Boiko NI, Khavinson VKh. The treatment with the polypeptide preparation «Prostatilen» of patients with prostatitis complicated by a sexual functional disorder // Vrach Delo. 1991 Feb; (2): 48–51.
Vozianov A.F., Gorpynchenko I.I., Boiko N.I., Drannik GN, Khavinson VKh The use of prostatilen in treating patients with prostatic diseases // Urol Nefrol (Mosk). 1991 Nov Dec;(6):43–6.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF) a multidimensional scale for assessment of erectile dysfunction. Urology. 1997 Jun; 49(6):822–30.